SEC Form 4 · accession 0000899243-18-006964
Global Blood Therapeutics, Inc. · GBT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Hing Sham
Officer — See Remarks
Period of report
Mar 7, 2018
Accepted (ET)
Mar 9, 2018 · 5:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001629137
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 7, 2018 | M | 10,714 | $0.49 | A | 98,215 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $0.49 | Mar 7, 2018 | M | 10,714 | D | — | Sep 9, 2024 | Common Stock | 10,714 | 10,715 | D |
Explanation of responses
- F125% of the shares subject to this option shall vest and become exercisable on July 28, 2015, and the remaining shares subject to this option shall vest and become exercisable in 12 equal quarterly installments thereafter.
Remarks
Senior Vice President, Research